Lorlatinib Exposure-Response Analyses for Safety and Efficacy in a Phase I/II Trial to Support Benefit-Risk Assessment in Non-Small Cell Lung Cancer

Joseph Chen, Ana Ruiz-Garcia, Leonard P James, Gerson Peltz, Holger Thurm, Jill Clancy, Jennifer Hibma, Joseph Chen, Ana Ruiz-Garcia, Leonard P James, Gerson Peltz, Holger Thurm, Jill Clancy, Jennifer Hibma

Abstract

Lorlatinib is a small molecule inhibitor of anaplastic lymphoma kinase (ALK) and c-ROS oncogene 1 (ROS1) tyrosine kinases and is approved for the treatment of patients with ALK-positive advanced non-small cell lung cancer (NSCLC). In the phase I/II study (NCT01970865), potential exposure-response (E-R) relationships between lorlatinib and selected safety and efficacy end points were evaluated in patients with NSCLC. E-R relationships were assessed for safety end points with incidence > 10% in all treated patients (n = 328). In total, 4 safety end points were assessed: hypercholesterolemia grade ≥ 3, hypertriglyceridemia grade ≥ 3, weight gain grade ≥ 2, and treatment-emergent adverse events (TEAEs) grade ≥ 3. Using logistic regression, significant relationships were identified between lorlatinib plasma exposure and risk of hypercholesterolemia grade ≥ 3 (odds ratio (OR) 5.256) and risk of TEAE grade ≥ 3 (OR 3.214). The covariates baseline cholesterol and time on study prior to the event (TE) were associated with the probability of hypercholesterolemia grade ≥ 3. Baseline cholesterol and TE were found to have a statistically significant correlation with TEAE grade ≥ 3. Exposure-efficacy relationships were assessed for objective response rate (ORR; n = 197) and intracranial objective response rate (IC-ORR; n = 132). Lorlatinib plasma exposure was not identified as a statistically significant factor related to either efficacy end point. The only significant E-R relationships identified for efficacy were between baseline alkaline phosphatase and baseline amylase with IC-ORR (ORs 0.363 and 1.015, respectively). These findings support the lorlatinib indicated dose and dose modification guidelines regarding the management of lorlatinib-related AEs.

Conflict of interest statement

J.C., A.R.‐G., L.P.J., G.P., H.T., J.C., and J.H. are current or former employees of Pfizer Inc.

© 2021 Pfizer Inc. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.

Figures

Figure 1
Figure 1
Predicted probability of hypercholesterolemia grade ≥ 3 vs. Cmax prior to the AE. The dashed lines represent the 10th, 50th, and 90th percentiles of Cmax event for patients in the safety analysis population dosed at 100 mg q.d. The black line is the median predicted probability and the gray ribbon is the 95% confidence interval of the predicted probability. Note that Cmax event is presented instead of log(Cmax event) for ease of interpretation. Time on study prior to the event was fixed to the analysis population median of 41 days and baseline cholesterol was fixed to the analysis population median of 193 mg/day. AE, adverse event; Cmax event, maximum observed concentration prior to the adverse event; q.d., once daily.
Figure 2
Figure 2
Predicted probability of TEAE grade ≥ 3 vs. Ctrough ss. The dashed lines represent the 10th, 50th, and 90th percentiles of Ctrough ss for patients in the safety analysis population dosed at 100 mg q.d. The black line is the median predicted probability and the gray ribbon is the 95% prediction interval of the predicted probability. Note that Ctrough ss is presented instead of log(Ctrough ss) for ease of interpretation. Time on study prior to the event was fixed to the analysis population median of 38.75 days and age fixed to the analysis population median of 193 mg/dL. Ctrough ss, trough concentration at steady‐state; q.d., once daily; TEAE, treatment‐emergent adverse event.

References

    1. Global Burden of Disease Cancer Collaboration . Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability‐adjusted life‐years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA Oncol. 5, 1749–1768 (2019).
    1. Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359–E386 (2015).
    1. American Cancer Society . Cancer facts & figures. The Society (2008).
    1. Bergethon, K. et al. ROS1 rearrangements define a unique molecular class of lung cancers. J. Clin. Oncol. 30, 863–870 (2012).
    1. Rimkunas, V.M. et al. Analysis of receptor tyrosine kinase ROS1‐positive tumors in non‐small cell lung cancer: identification of a FIG‐ROS1 fusion. Clin. Cancer Res. 18, 4449–4457 (2012).
    1. Lin, J.J. & Shaw, A.T. Resisting resistance: targeted therapies in lung cancer. Trends Cancer 2, 350–364 (2016).
    1. Zou, H.Y. et al. PF‐06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models. Cancer Cell 28, 70–81 (2015).
    1. Johnson, T.W. et al. Discovery of (10R)‐7‐amino‐12‐fluoro‐2,10,16‐trimethyl‐15‐oxo‐10,15,16,17‐tetrahydro‐2H‐8,4‐(metheno)pyrazolo[4,3‐h][2,5,11]‐benzoxadiazacyclotetradecine‐3‐carbonitrile (PF‐06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c‐ROS oncogene 1 (ROS1) with preclinical brain exposure and broad‐spectrum potency against ALK‐resistant mutations. J. Med. Chem. 57, 4720–4744 (2014).
    1. Shaw, A.T. et al. Lorlatinib in non‐small‐cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open‐label, single‐arm first‐in‐man phase 1 trial. Lancet Oncol. 18, 1590–1599 (2017).
    1. Solomon, B.J. et al. Lorlatinib in patients with ALK‐positive non‐small‐cell lung cancer: results from a global phase 2 study. Lancet Oncol. 19, 1654–1667 (2018).
    1. Shaw, A.T. et al. Lorlatinib in advanced ROS1‐positive non‐small‐cell lung cancer: a multicentre, open‐label, single‐arm, phase 1–2 trial. Lancet Oncol. 20, 1691–1701 (2019).
    1. Syed, Y.Y. Lorlatinib: first global approval. Drugs 79, 93–98 (2019).
    1. Kwak, E.L. et al. Anaplastic lymphoma kinase inhibition in non‐small‐cell lung cancer. N. Engl. J. Med. 363, 1693–1703 (2010).
    1. Chen, J. , Houk, B.., Pithavala, Y.K. , Clancy, J. & Ruiz, A. Development of a population pharmacokinetic model for lorlatinib using pooled data from non‐small cell lung cancer patients and healthy volunteers. American College of Clinical Pharmacology (ACCP) Annual Meeting (2018).
    1. US Department of Health and Human Services , National Cancer Institute . Common terminology criteria for adverse events (CTCAE) version 4.03. (2010).
    1. R Core Team . R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria: <> (2019).
    1. Nickens, D. & Tan, W. Exposure‐Response Analysis of Efficacy and Safety Endpoints for Crizotinib in the Treatment of Patients with ALK‐Positive Non‐Small Cell Lung Cancer (NSCLC). In Annual American Conference on Pharmacometrics.
    1. Gadgeel, S.M. et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib‐resistant ALK‐rearranged non‐small‐cell lung cancer (AF‐002JG): results from the dose‐finding portion of a phase 1/2 study. Lancet Oncol. 15, 1119–1128 (2014).
    1. Morcos, P.N. et al. Exposure‐response analysis of alectinib in crizotinib‐resistant ALK‐positive non‐small cell lung cancer. Cancer Chemother. Pharmacol. 82, 129–138 (2018).
    1. Smart, K. et al. Alectinib exposure‐response (ER) in ALK‐inhibitor naïve ALK‐positive NSCLC patients: pooled analysis across phase III studies. J. Clin. Oncol. 37, e20575 (2019).
    1. Groenland, S.L. et al. Exposure‐response analyses of anaplastic lymphoma kinase inhibitors crizotinib and alectinib in non‐small cell lung cancer patients. Clin. Pharmacol. Ther. 109, 394–402 (2021).
    1. FDA Center for Drug Evaluation and Research . Ceritinib summary review <> (2014).
    1. European Medicines Agency . Alunbrig assessment report (2018).
    1. Gupta, N. et al. Population pharmacokinetic (PK) and exposure‐response analyses from the pivotal ALTA‐1L study: model‐based analyses supporting the brigatinib dose in patients with anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC). J. Clin. Oncol. 38, e21725 (2020).
    1. Cho, B.C. et al. Efficacy and safety of ceritinib (450 mg/d or 600 mg/d) with food versus 750‐mg/d fasted in patients with ALK receptor tyrosine kinase (ALK)‐positive NSCLC: primary efficacy results from the ASCEND‐8 study. J. Thorac. Oncol. 14, 1255–1265 (2019).
    1. FDA Center for Drug Evaluation and Research . Brigatinib Multi‐Discipine Review (2017).

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren